Clinical Trial Update: Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial of peginterferon alfa-2b in younger patients with recurrent or surgically unresectable craniopharyngioma was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Craniopharyngioma

Drugs mentioned

• Peginterferon alfa-2b (Peginterferon alfa-2b)

Snippet

Sponsor: Pediatric Brain Tumor Consortium | Conditions: Childhood Craniopharyngioma | Phase 2 | Status: TERMINATED | Results posted: 2020-02-24